Key Takeaways
- • A University of California, Berkeley study published May 18, 2021, documents that private equity business practices significantly undermine competition and stability in the healthcare industry, based on a decade of empirical evidence.
- • Private equity ownership correlates with accelerated market consolidation, higher patient costs, and worse outcomes for Medicare beneficiaries, with price increases in PE-affected markets running 1.5 to 3 times higher than competitive markets.
- • Approximately 460 U.S. hospitals are currently controlled by private equity firms, representing a substantial and growing footprint in the healthcare sector alongside expanded PE presence in physician practices and nursing facilities.
- • PE's investment strategy prioritizes short-term revenue generation and consolidation over competitive dynamics, creating structural incentives that destabilize healthcare markets and increase patient financial and clinical risk.
Summary
A comprehensive study from UC Berkeley's School of Public Health, released on May 18, 2021, presents a decade of evidence documenting the negative effects of private equity investment on healthcare market competition and industry stability. The research builds on mounting academic findings showing that PE ownership patterns correlate with measurably worse outcomes across multiple healthcare dimensions.
The study identifies private equity's core business model—focused on rapid consolidation and short-term revenue extraction—as fundamentally misaligned with competitive healthcare markets. Rather than improving operational efficiency or service delivery, PE-backed consolidation appears to reduce competitive pressure and enable price increases. In markets where PE firms have acquired healthcare providers, price increases for key services run between 1.5 and 3 times higher than in competitive markets, according to the research. Additionally, Medicare patient outcomes show statistically significant deterioration under PE ownership, and patients report increased rates of service disruptions and access issues.
The scale of PE penetration in U.S. healthcare is substantial. Approximately 460 hospitals operate under private equity control, while PE investments have expanded well beyond traditional hospital and nursing facility targets into physician practices and other healthcare segments. This rapid expansion of PE capital into healthcare—what researchers term "soaring investment"—has accelerated consolidation while simultaneously eroding the market conditions necessary for competition and innovation.
The findings align with concurrent research from the National Bureau of Economic Research and other institutional sources, creating a convergent body of evidence on PE's structural impact on healthcare dynamics. For institutional investors and family offices evaluating healthcare allocations or PE fund commitments with healthcare exposure, the study underscores regulatory and competitive risks emerging from further consolidation driven by PE acquisition strategies.
The study identifies private equity's core business model—focused on rapid consolidation and short-term revenue extraction—as fundamentally misaligned with competitive healthcare markets. Rather than improving operational efficiency or service delivery, PE-backed consolidation appears to reduce competitive pressure and enable price increases. In markets where PE firms have acquired healthcare providers, price increases for key services run between 1.5 and 3 times higher than in competitive markets, according to the research. Additionally, Medicare patient outcomes show statistically significant deterioration under PE ownership, and patients report increased rates of service disruptions and access issues.
The scale of PE penetration in U.S. healthcare is substantial. Approximately 460 hospitals operate under private equity control, while PE investments have expanded well beyond traditional hospital and nursing facility targets into physician practices and other healthcare segments. This rapid expansion of PE capital into healthcare—what researchers term "soaring investment"—has accelerated consolidation while simultaneously eroding the market conditions necessary for competition and innovation.
The findings align with concurrent research from the National Bureau of Economic Research and other institutional sources, creating a convergent body of evidence on PE's structural impact on healthcare dynamics. For institutional investors and family offices evaluating healthcare allocations or PE fund commitments with healthcare exposure, the study underscores regulatory and competitive risks emerging from further consolidation driven by PE acquisition strategies.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.